Aims: This study aimed to assess clinicopathologic features of transactive response DNA-binding protein of 43 kDa (TDP-43) pathology and its risk factors in multiple system atrophy (MSA). Methods: Paraffin-embedded sections of the amygdala and basal forebrain from 186 autopsy-confirmed MSA cases were screened with immunohistochemistry for phospho-TDP-43. In cases having TDP-43 pathology, additional brain regions were assessed. Immunohistochemical and immunofluorescence double-staining and immunogold electron microscopy (IEM) were performed to evaluate colocalization of TDP-43 and a-synuclein. Genetic risk factors for TDP-43 pathology were also analysed. Results: Immunohistochemistry showed various morphologies of TDP-43 pathology in 13 cases (7%), such as subpial astrocytic inclusions, neuronal inclusions, dystrophic neurites, perivascular inclusions and glial cytoplasmic inclusions (GCIs). Multivariable logistic regression models revealed that only advanced age, but not concurrent Alzheimer's disease, argyrophilic grain disease or hippocampal sclerosis, was an independent risk factor for TDP-43 pathology in MSA (OR: 1.11, 95% CI: 1.04-1.19, P = 0.002). TDP-43 pathology was restricted to the amygdala in eight cases and extended to the hippocampus in two cases. The remaining three cases had widespread TDP-43 pathology. Immunohistochemical and immunofluorescence double-staining and IEM revealed colocalization of a-synuclein and TDP-43 in GCIs with granule-coated filaments. Pilot genetic studies failed to show associations between risk variants of TMEM106B or GRN and TDP-43 pathology. Conclusions: TDP-43 pathology is rare in MSA and occurs mainly in the medial temporal lobe. Advanced age is a risk factor for TDP-43 pathology in MSA. Colocalization of TDP-43 and a-synuclein in GCIs suggests possible direct interaction between the two molecules.
Introduction
Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by variable combinations of autonomic failure, parkinsonism, cerebellar ataxia and pyramidal symptoms [1] . Some MSA patients develop cognitive impairment, mainly executive dysfunction [2] [3] [4] . In rare cases, so-called atypical MSA, patients show clinical phenotypes of frontotemporal dementia (FTD), including corticobasal syndrome or behavioural variant FTD [5] . Pathologically, MSA is classified as an a-synucleinopathy, and glial cytoplasmic inclusions (GCIs) in oligodendrocytes are the pathognomic features of the disorder [1, 6] . GCIs are found throughout the brain, with a predilection for striatonigral and olivopontocerebellar systems [7] . As with other neurodegenerative diseases, age is one of the risk factors for MSA; therefore, pathological hallmarks of other age-related neurodegenerative diseases sometimes coexist with MSA and may modify its clinical phenotype [8, 9] .
Transactive response DNA-binding protein of 43 kDa (TDP-43) aggregates in the frontotemporal cortex and motor neurons are pathologic hallmarks of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis [10] [11] [12] . In addition to these disorders, TDP-43 pathology has also been reported in other neurodegenerative diseases, including Alzheimer's disease (AD) [11] [12] [13] [14] [15] [16] [17] [18] , Lewy body disease (LBD) [12, 15, [19] [20] [21] , hippocampal sclerosis [22] [23] [24] , Perry syndrome [25, 26] , progressive supranuclear palsy (PSP) [20, 27] , corticobasal degeneration [17, 28] , argyrophilic grain disease (AGD) [29, 30] and MSA [31] . TDP-43 pathology progresses in a stereotypical pattern in each disease, but the distribution is distinct among neurodegenerative diseases, suggesting that vulnerability to TDP-43 could be associated with vulnerability unique to each neurodegeneration disorder [32] . Geser et al. demonstrated that 14% (4 of 29) of MSA cases had TDP-43 aggregates in dystrophic neurites (DNs) and perivascular inclusions, but not in GCIs, predominantly in the medial temporal lobe and subcortical regions [31] . These findings suggest that TDP-43 pathology in MSA is a concomitant age-related change, rather than a primary pathologic feature of the disease.
The aims of this study were to determine the frequency, clinicopathologic features and risk factors for TDP-43 pathology in MSA. To this end, we screened TDP-43 pathology using a large cohort of MSA cases; assessed concurrent pathologies, including AD, AGD, Lewy-related pathology and hippocampal sclerosis; and reviewed medical records to explore possible clinicopathologic correlations. Genetic variants of TMEM106B and GRN, which are risk modifiers for TDP-43 pathology [33, 34] , were also analysed.
Subjects and Methods

Case selection and ethical approval
Between 1998 and 2017, 211 cases in the Mayo Clinic brain bank have been given a neuropathologic diagnosis of MSA. Of these, 186 cases with available paraffin-embedded tissue and at least minimal medical documentation were included in this study. Brain autopsies were obtained after consent of the legal nextof-kin or individuals with legal power-of-attorney, and studies of autopsy samples are considered exempt from human subject research by the Mayo Clinic Institutional Review Board.
Neuropathologic assessment
Formalin-fixed brains underwent systematic and standardized sampling with neuropathologic evaluation by a single, experienced neuropathologist (D.W.D) [35] . Paraffin-embedded 5-lm-thick sections mounted on glass slides were stained with haematoxylin and eosin (H&E) and thioflavin S stains. Braak neurofibrillary tangle (NFT) stage and Thal amyloid phase were assigned using thioflavin S fluorescent microscopy according to published criteria [36] [37] [38] . Immunohistochemistry for a-synuclein (NACP, 1:3000 rabbit polyclonal) [39] was performed on sections of the basal forebrain, striatum, midbrain, pons, medulla and cerebellum to establish a neuropathologic diagnosis of MSA [6] . The severity of a-synuclein pathology, including GCIs, neuronal cytoplasmic inclusions (NCIs) and DNs was graded semiquantitatively on a five-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe) [3] . Neuropathological diagnosis of AD was based on the consensus criteria for the neuropathologic diagnosis of AD [40] . Sections of the amygdala at the level of the anterior commissure were immunostained with anti-phospho-tau antibody (CP13, 1:1000, from Dr Peter Davies, Feinstein Institute, North Shore Hospital, NY) to establish neuropathological diagnosis of AGD [41] . Select sections were processed for Gallyas silver stain and 4-repeat tau (RD4, 1:5000; Millipore, Temecula, CA) immunohistochemistry to assist in neuropathological diagnosis of AGD. Lewy-related pathology was assessed in the cortex, amygdala, basal forebrain and brainstem, and classified as brainstem, transitional, or diffuse Lewy body disease [42] . Hippocampal sclerosis was assessed by H&E staining as previously described [21] .
TDP-43 immunohistochemistry
To characterize TDP-43 pathology in MSA, TDP-43 pathology in 186 MSA cases was screened. Sections from the amygdala, basal forebrain, putamen, globus pallidus and anterior hypothalamus at the level of the anterior commissure were immunostained with anti-phospho-TDP43 antibody (pS409/410, mouse monoclonal, 1:5000, Cosmo Bio, Tokyo, Japan) using a DAKO Autostainer (Universal Staining System, Carpinteria, CA). For cases having TDP-43 pathology in these sections, additional sections of the motor cortex, anterior hippocampus at the level of subthalamic nucleus, thalamus, midbrain, pons, medulla and cerebellar hemisphere with dentate nucleus were also screened. All slides were reviewed simultaneously by two observers (D.W.D., S.K.) who agreed on the presence of TDP-43 immunoreactivity, defined as NCI, GCI, DNs, fine neurites, neuronal intranuclear inclusions, spheroids or perivascular inclusions in any region. The severity of TDP-43 pathology was graded semiquantitatively on a four-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe) [27] .
To identify perivascular inclusions, a section including the hippocampus from a case (MSA-12) was processed for double-labelling immunohistochemistry with the combination of anti-TDP-43 antibody (MC2085, 1:1000 rabbit polyclonal, from Dr. Leonard Petrucelli, Mayo Clinic) and anticollagen IV antibody (1:1000 mouse monoclonal, MP Biomedicals, Solon, OH) using a previously published method [43] . To screen for colocalization of a-synuclein and TDP-43 aggregates, sections including the thalamic fasciculus from three cases (MSA-11-13) and sections including the hippocampus from three cases (MSA-9, -10 and -12) were processed for double-labelling immunohistochemistry with the combination of a-synuclein (NACP, 1:3000) and anti-phospho-TDP-43 antibody (pS409/410, 1:5000).
Immunofluorescence double-staining
Immunofluorescence double-staining with the combination of a-synuclein and phospho-TDP-43 was performed to confirm colocalization of the two proteins. The deparaffinized and rehydrated sections of the thalamic fasciculus of MSA-13 were pretreated with 95% formic acid for 30 min and then steamed in distilled water for 30 min. Next, sections were blocked with Protein Block plus Serum Free (DAKO) for 1 h and incubated with both anti-phospho-TDP43 antibody (1:500) and anti-NACP (1:2000) primary antibodies diluted in with Antibody Diluent with BackgroundReducing Components (DAKO) overnight at 4°C. Sections were washed three times with 1xPBS at room temperature, and then incubated with secondary antibodies Alexa Fluor 568 (1:500, Thermo Fisher Scientific, Inc.) and Alexa Fluor 488 (1:500, Thermo Fisher Scientific, Inc.) diluted with Antibody Diluent with Background-Reducing Components (DAKO) for 1.5 h at room temperature in a dark chamber. Sections were washed three times with 1xPBS at room temperature, incubated with 1% Sudan Black for 2 min, washed with distilled water and mounted with Vectashield mounting media containing DAPI (Vector Laboratories). Representative images were taken with a confocal laser-scanning fluorescent microscope (LSM 800; Carl Zeiss, Jena, Germany).
Postembedding immunogold electron microscopy
A piece of thalamic fasciculus from formalin-fixed brain of MSA-13 was processed for immunogold electron microscopy (IEM) as described previously [44] . Rabbit polyclonal antibodies to a-synuclein [39] and TDP-43 (ProteinTech Group, Chicago, IL) were used. Goat anti-rabbit IgG conjugated with 18 nm colloidal gold particles was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). For TDP-43 IEM, thin sections collected on Formvar-coated nickel grids were treated with citrate buffer, pH 6, for 10 min at 95°C before antibody incubation. EM images were obtained with a Gatan 831 Orius digital camera fitted in a Philips 208S electron microscope, and processed using Photoshop software.
Clinical assessment
Clinical information in all MSA cases was assessed as previously described [3, 35, 45] . Antemortem clinical information for age at symptom onset, family history of dementia or parkinsonism, clinical diagnosis and clinical symptoms and signs (autonomic dysfunctions, parkinsonism, cerebellar ataxia, cognitive impairment, etc.) were gathered from medical records and a brain bank questionnaire filled out by a close family member. Based on clinical information, each patient was assigned an MSA clinical subtype: MSA with predominant parkinsonism (MSA-P) or MSA with predominant cerebellar ataxia (MSA-C).
Genetic analysis
Genetic analyses in cases with available frozen tissue were performed: 12 TDP-43-positive cases and 153 TDP-43-negative cases. For genotyping, genomic DNA was extracted from the cerebellum of frozen brain tissue using standard procedures. Genotyping for GRN (SNP rs5848 C/T SNPs, T minor allele) and TMEM106B (rs3173615 C/G SNPs, G minor allele) was assessed with TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA) as previously reported [10, [46] [47] [48] . Genotype calls were obtained with QuantStudio TM Real-Time PCR Software (Applied Biosystems). In addition, pathogenic SNCA substitutions (A30P, A53T) were screened using the Sequenom MassArray iPLEX platform.
Statistical analysis
All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University Saitama, Japan), which is a graphical interface for R 3.1.1 (The R Foundation for Statistical Computing, Vienna, Austria) [49] . A chi-square test or Fisher's exact test was performed for group comparisons of categorical data, as appropriate. The t-test or Mann-Whitney rank sum test was used for analyses of continuous variables, as appropriate. P-values <0.05 were considered statistically significant. Multivariable logistic regression models were built to identify independent risk factors for TDP-43 pathology using the variables with borderline significance (P < 0.15) on univariate analysis.
Results
Clinicopathologic features of MSA cases with TDP-43 pathology
Of the 186 MSA cases, 13 (7%) had TDP-43 pathology in screening sections. Table 1 summarizes clinicopathologic features of MSA cases with TDP-43 pathology compared with cases without TDP-43 pathology. The median age at death was significantly older than that of cases without TDP-43 pathology (73 vs. 65, P = 0.015). As shown in Figure 1 , when cases were divided into three age groups (i.e. 65<, 65-79 and ≥80 years), the frequency of TDP-43 pathology was significantly higher in the age group ≥80 years compared to the two younger groups (35% vs. 4% vs. 4%, P < 0.001). Disease duration and the ratio of clinical subtype of MSA (i.e. MSA-P and MSA-C) were not different between TDP-43-positive and -negative cases. It is worth noting that two of the TDP-43-positive cases were atypical MSA, which were clinically diagnosed with corticobasal syndrome (MSA-7) or progressive nonfluent aphasia (MSA-8) as previously reported [5] . Median Braak NFT stage was higher in TDP-43-positive cases than TDP-43-negative cases (II vs. I, P = 0.007). Chi-square test reveals that the frequency of TDP-43 pathology in the ≥80 years age group is significantly higher compared to the other two age groups (P < 0.001).
Regarding concurrent pathologies, AD, AGD, hippocampal sclerosis and Lewy-related pathology were more frequently observed in TDP-43-positive cases than in TDP-43-negative cases; of these, only hippocampal sclerosis reached statistical significance (P = 0.005).
Multivariable logistic regression models using the variables with borderline significance (P < 0.15) on univariate analysis (i.e. age, Braak NFT stage, AD, AGD and hippocampal sclerosis) revealed that only age was an independent risk factor for TDP-43 pathology in MSA (OR: 1.11, 95% CI: 1.04-1.19, P = 0.002). Clinical diagnosis, disease duration, clinical symptoms and neurological signs of each TDP-43-positive case are given in Table S1 .
Distribution and morphology of TDP-43 pathology
A range of morphologic lesions were TDP-43 immunopositive ( Figure 2 ), with lesions in both neurons and glia. Table 2 summarizes the distribution, morphology and severity of TDP-43 pathology, as well as concurrent pathologies, of all 13 TDP-43-positive cases.
The amygdala was the most vulnerable region to contain TDP-43 pathology; 12 of 13 cases were positive. Subpial astrocytic lesions ( Figure 2A) were the most frequent in the amygdala, mainly in the semilunar and ambient gyri, and observed in seven cases (MSA-1-7). Of these, subpial astrocytic lesions were the only TDP-43 pathology in four cases (MSA-1-4). Six cases (MSA-5-9 and -13) had sparse NCIs in the amygdala: just one or two aggregates in the entire section. MSA-10 had numerous NCIs and a few DNs (Figure 2B) , and MSA-12 showed abundant short DNs ( Figure 2C ) in the amygdala. Spheroids and perivascular inclusions characterized by small, globular, dense structures in close proximately to small vessels were rarely seen in the amygdala. The hippocampus, entorhinal cortex and dentate gyrus were affected in four cases respectively. NCIs were commonly observed in the hippocampal pyramidal cell layer ( Figure 2D ), entorhinal cortex and dentate gyrus ( Figure 2E ). Two cases (MSA-12 and -13) had fine neurites in the hippocampal CA1 subfield ( Figure 2F ), which were consistent with hippocampal sclerosis or prehippocampal sclerosis. A few perivascular inclusions were observed in the hippocampal CA1 and entorhinal cortex (Figure 2G) . Oligodendroglial inclusions were detected in the hippocampal alveus, fimbria and white matter of parahippocampal gyrus. Neuronal intranuclear inclusions were rarely detected in the hippocampus (Figure 2H) . Subcortical structures, such as the thalamus, basal forebrain and hypothalamus and brainstem were affected in three cases. GCIs, NCIs and DNs were commonly seen in these regions ( Figure 2I,J) . Scattered neuronal intranuclear inclusions were detected in the substantia nigra in MSA-11. The medulla, cerebellum and neocortices were affected in one case (MSA-13). An isolated GCI was detected in the entire section of cerebellar white matter, and moderate amounts of GCIs and spheroids ( Figure 2K) were observed in the motor cortex.
Colocalization of a-synuclein and TDP-43 in GCIs
To examine whether TDP-43 aggregates are colocalized with a-synuclein pathology, double-staining immunohistochemistry of these two proteins were performed in five cases (MSA-9-13). Colocalization of the two proteins was not observed in the hippocampus and adjacent areas in three cases (MSA-9, -10 and -12). Sections including the thalamus were double-stained in three cases (MSA-11-13). MSA-11 did not show any colocalization, whereas the other two cases showed that some GCIs in the thalamic fasciculus (MSA-12 and -13) and in the mammillothalamic tract (MSA-13) were labelled by both a-synuclein and phospho-TDP-43 ( Figure 2L,M) . In MSA-13, approximately 1% of asynuclein-positive GCIs in the mammillothalamic tract and 13% of those in the thalamic fasciculus showed colocalization with phospho-TDP-43. An adjacent section of the thalamic fasciculus from MSA-13 was also processed for immunofluorescence double-staining. Confocal z-stack microscopy revealed colocalization of a-synuclein and phospho-TDP-43 in a subset of GCIs ( Figure 2N-P) .
Immunogold electron microscopy
To confirm the colocalization of the two proteins, IEM using semiserial sections of the thalamic fasciculus from MSA-13 was performed. IEM showed that GCIs were densely packed granule-associated filaments, heavily labelled with antibody to a-synuclein and moderately to TDP-43 respectively (Figure 3) . This confirms the colocalization of both proteins by immunohistochemistry and immunofluorescence double-labelling ( Figure 2L-P) . Ultrastructurally, the labelled granulecoated filaments were similar to previous reports, with a diameter of~15 nm in uncoated segments of the filaments [12, 50] . The similar morphology makes it difficult to determine if a filament has one or both proteins.
Genetic analysis
To determine if reported genetic risk variants for FTLD-TDP could contribute to TDP-43 pathology in MSA, genetic analyses were performed. As shown in Table 3 , AGD, argyrophilic grain disease; AM, amygdala; BF, basal forebrain; CW, cerebellar white mater; D, dystrophic neurites; DD, disease duration; DG, dentate gyrus; EC, entorhinal cortex; FN; fine neurites; G, glial cytoplasmic inclusions; HP, hippocampus; HS, hippocampal sclerosis; I, neuronal intranuclear inclusions; LP, Lewy-related pathology; MB, midbrain; MC, motor cortex; ME, medulla; N, neuronal cytoplasmic inclusions; P, subpial astrocytic inclusions; PN, pontine nucleus; TH, thalamus; V, perivascular inclusions.
minor allele frequency of TMEM106B and GRN were not significantly different between TDP-43-positive and -negative cases.
Clinicopathologic features in MSA-13
A unique widespread TDP-43 pathology of MSA-13 encouraged us to investigate clinicopathologic features of this case; thus, a clinical vignette and results of immunohistochemistry for a-synuclein, phospho-TDP-43 and phospho-tau are described here.
The patient was a 61-year-old Caucasian man who had a family history of autopsy-confirmed Lewy body disease (clinically diagnosed with Parkinson disease) in his mother. He developed erectile dysfunction at age 50 and left leg tremor at age 53. Subsequently, he developed imbalance with falls, urinary incontinence and retention, constipation, lightheadedness, difficulty swallowing and voice hoarseness. He was diagnosed with orthostatic hypotension and began midodrine and fludrocortisone at age 56. Short-term memory loss began at that time. DaTscan detected loss of dopaminergic neuronal terminals in the striatum. He was diagnosed with probable MSA-P at age 57. Macroscopically, the neocortex, hippocampal formation and amygdala were free of atrophy. The basal ganglia showed no atrophy and only subtle discoloration of the lateral and posterior putamen. Horizontal sections of the midbrain and pons are remarkable for marked pontine atrophy and mild loss of pigment in the substantia nigra and locus coeruleus. There is marked atrophy of the middle cerebellar peduncle, pontine base and cerebellar white matter. Immunohistochemistry for a-synuclein revealed widespread distribution of GCIs, consistent with a pathological diagnosis of MSA. Table 4 summarizes the severity and distribution of asynuclein and TDP-43 pathology of this case. As shown in a section of double-staining, the mammillothalamic tract and thalamic fasciculus had numerous a-synuclein-positive GCIs ( Figure 4A ,B) and moderate amount of TDP-43-positive GCIs (Figure 4C,D) . Abundant a-synuclein-positive NCIs in the hippocampal pyramidal cell layer ( Figure 4E ) and dentate gyrus (Figure 4F ) resembled atypical MSA [5] , but neuronal loss was minimal in these regions. The hippocampal CA1 showed some TDP-43-positive NCIs and diffuse fine neurites ( Figure 4G ), which were consistent with prehippocampal sclerosis [21] , whereas the dentate gyrus was spared ( Figure 4H ). The transverse pontine fibres had abundant a-synuclein-positive DNs ( Figure 4I ), but TDP-43 immunohistochemistry showed a few GCIs in this region ( Figure 4J ). TDP-43-positive NCIs were rarely detected in the locus coeruleus. The inferior olivary nucleus had numerous a-synuclein-positive NCIs, GCI and DNs ( Figure 4K) , and moderate amount of TDP-43-positive GCIs and a few NCIs ( Figure 4L ). TDP-43-positive GCIs and DNs were seen in the subcortical white matter, most frequent in white matter adjacent to the motor cortex. Immunohistochemistry for phospho-tau and 4-repeat tau revealed abundant argyrophilic grains, pretangles, balloon neurons and coiled body in the amygdala, hippocampus and parahippocampal gyrus, which were consistent with AGD ( Figure 4M-O) . Thioflavin S microscopy revealed no Alzheimer-type pathology (Braak NFT stage and Thal amyloid phase were 0).
Genetic analysis revealed that the patient did not have risk alleles in either TMEM106B or GRN. Since the patient had a family history of autopsy-confirmed LBD, a-synuclein-encoding gene SNCA was also analysed; however, any mutations within exons 2 and 3 of SNCA were found.
Discussion
In a cohort of 186 cases of pathologically confirmed MSA, this study identified 13 (7%) cases with TDP-43 immunoreactivity in sections of the amygdala and basal forebrain. Most cases had TDP-43 pathology restricted to the medial temporal regions, but three cases had widespread pathology in subcortical structures and brainstem. Colocalization of a-synuclein and TDP-43 was identified in a subset of GCIs in two cases.
As with AD and elderly healthy individuals [13, 51] , the amygdala was the most vulnerable region to contain TDP-43 pathology in MSA; eight cases had this pathology restricted to the amygdala. Four cases had only subpial astrocytic lesions in the semilunar and ambient gyri, which might be an earliest change in TDP-43 pathology. In contrast, MSA-vulnerable regions, such as the putamen, substantia nigra, medulla, pons and cerebellum, do not seem to be as vulnerable to TDP-43 pathology. More cases are necessary to conclude whether there is region-specific vulnerability to TDP-43 pathology.
IEM of serial sections is in agreement with immunohistochemistry and immunofluorescence double-staining, and further showed GCIs contain filaments associated with dense granular material. The packed and intermingled appearance in oligodendrocytes contrasts with previous reports of colocalization of a-synuclein and tau in neurons of AD with amygdala Lewy bodies [44, 52] . In the latter case, the uncoated tau Genetic analysis is performed for TDP-positive (N = 12) and TDPnegative (N = 153) respectively.
filaments could be distinguished from granule-coated filaments of a-synuclein. Moreover, tau aggregates were spatially separate from aggregated a-synuclein, despite their close proximity. The mixed morphology in GCIs of MSA could be due to physical constraint of a small cytoplasm of oligodendrocytes forcing crowding of the filaments together. The nature of dense granular material is not clear. It would be interesting to see if coexisting a-synuclein and TDP-43 would mix or segregate in neurons, which have a larger cytoplasm. In this study, multiple regression models indicated that age was an independent risk factor for TDP-43 pathology in MSA. Not only patients with neurodegenerative diseases, but cognitively normal elderly individuals also have TDP-43 pathology, especially DNs, in the medial temporal regions [30, 51, 53] . A recent meta-analysis showed that the estimated prevalence of TDP-43 proteinopathy in cognitively normal elderly individuals (age: 80.2 AE 8.5 years) was 24% (95% CI: 13%-34%) [54] . The frequency of TDP-43 pathology in this study was much lower than that of cognitively normal elderly individuals, probably because of younger age of death (66.7 AE 8.5 years) in the MSA cohort in this study [31] . Indeed, when restricted to patients 80 years of age or older, the frequency of TDP-43 pathology increased to 35% in the present MSA cohort, which is within the range of other studies of TDP-43 in cognitively normal elderly individuals [54] .
Besides age, several risk factors for TDP-43 pathology, such as AD, AGD and hippocampal sclerosis were frequent in TDP-43-positive cases, although multiple regression models failed to identify them as independent risk factors. This result should be interpreted cautiously because the number of MSA cases with concomitant pathology was too small to yield statistical difference; only eight cases had AD, and two cases had hippocampal sclerosis. Interestingly, three cases with the most widespread TDP-43 pathology (MSA-11-13) had concurrent AGD. Several studies reported the high [30] . Similarly, the previous study showed that concurrent AGD was a risk factor for TDP-43 pathology in PSP [27] . Taken together, AGD may be associated with TDP-43 pathology in MSA; however, it is still unknown whether AGD can cause widespread TDP-43 pathology beyond limbic structures affected by AGD. Additional screening of TDP-43 pathology in AGD is necessary to clarify the possible association between AGD and TDP-43 pathology. The possible impact of TDP-43 pathology on clinical manifestations was a focus of this study; however, neither the clinical subtype nor disease duration was different between TDP-43-positive and -negative cases. Given the fact that TDP-43 pathology is strongly associated with cognitive deficits (i.e. memory loss and naming) in the context of AD pathology [55] [56] [57] , cognitive impairment was also evaluated. Although four cases with TDP-43 pathology had documented cognitive impairment (Table 1) , in most it could be explained by other concurrent pathologies, such as AD, AGD and hippocampal sclerosis. Intriguingly, two cases were considered to have 'atypical MSA'. The previous study described these two cases were negative in TDP-43 pathology [5] ; however, this study found sparse TDP-43 pathology in the amygdala in both cases. Nevertheless, TDP-43 pathology is unlikely a key pathology of atypical MSA because the extent and severity of TDP-43 pathology was minimal. This study also described clinical features of MSA-13, the cases with the most widespread TDP-43 pathology. Unexpectedly, however, this patient appeared to have 'typical' MSA-P characterized by autonomic failure and parkinsonism. Although the patient complained of memory loss, this is sometimes observed in patients with MSA [3] . Taken together, this study did not find convincing impact of TDP-43 pathology on clinical manifestations in MSA.
Genetic analyses in this study were at variance with previous studies of TDP-43 in other neurodegenerative diseases. No statistically significant differences were found between MSA with and without TDP-43 pathology for TMEM106B rs3173615 and GRN. The small sample size of this cohort may contribute to this difference.
There are some limitations of this study. First, only sections of amygdala and basal ganglia were screened for TDP-43 pathology in all cases; thus, the frequency of this pathology in MSA may be an underestimate. Given the retrospective nature of this study, clinical information was limited. To evaluate possible clinical correlates of TDP-43 pathology, it will be important to evaluate MSA patients who come to autopsy from prospective clinical studies.
A notable strength of this study is the number of MSA cases screened for TDP-43 pathology, which is many fold greater than any previous study [31, 58] . This large number of cases allowed us to discover colocalization of TDP-43 and a-synuclein in GCIs, which were not described previously [31] . Another strength is the use of multiple methods to confirm colocalization, including immunohistochemical and immunofluorescence double-staining and IEM.
In conclusion, this study showed that about 7% of MSA have TDP-43 pathology, mainly in the medial temporal regions. Age is a risk factor for TDP-43 pathology in MSA. Given the fact that cases with extensive TDP-43 pathology often have concurrent AGD, we hypothesize that AGD play a role in exacerbating this pathology. This study identified colocalization of TDP-43 and a-synuclein in GCIs, which suggests possible association between the two pathologies at least in a subset of cases.
